Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer

NCT01259089 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

38

Enrollment

OTHER

Sponsor class

Conditions

Adenocarcinoma of the Lung
Non-small Cell Lung Cancer

Interventions

DRUG: erlotinib hydrochloride
DRUG: Hsp90 inhibitor AUY922
OTHER: laboratory biomarker analysis
PROCEDURE: needle biopsy
GENETIC: mutation analysis
OTHER: pharmacological study

Sponsor

Northwestern University

Collaborators

[object Object]